Single Encounter Radical Cure and Prophylaxis (SERCAP) describes an ideal anti-malarial drug that cures all malaria in a single dose. This target product profile has dominated anti-malarial drug discovery and development over the past decade. The operational advantage of a single encounter has to be balanced against the need for a high dose, reliable absorption, little variability in pharmacokinetic properties, slow elimination (to ensure curative drug exposures in all patients) and a very low rate of vomiting. The demanding aspirational target may have hindered anti-malarial drug development. Aiming for three-day regimens, as in current anti-malarial treatments, would be better.
Walter Taylor, Richard M. Hoglund, Pimnara Peerawaranun, Thuy-Nhien Nguyen, Tran Tinh Hien, Arnaud Tarantola, Lorenz von Seidlein, Rupam Tripura, Thomas J. Peto, Arjen M. Dondorp, Jordi Landier, François Nosten, Frank Smithuis, Koukeo Phommasone, Mayfong Mayxay, Soy Ty Kheang, Say Chy, Neeraj Kak, Rithea Leang, Dysoley Lek, Sim Kheng, Sinoun Muth, Arantxa Roca‐Feltrer, Mark Debackere, Rick M. Fairhurst, Ngak Song, Philippe Buchy, Didier Ménard, Sir Nicholas White, Joel Tärning, Mavuto Mukaka
Sir Nicholas White, Wirichada Pongtavornpinyo, Richard J. Maude, Sompob Saralamba, Ricardo Águas, Kasia Stepniewska, Sue J. Lee, Arjen M. Dondorp, Lisa J. White, Nicholas Day
James A Watson, Robert J. Commons, Joel Tärning, J. A. Simpson, Alejandro Llanos‐Cuentas, Marcus Lacerda, Justin A. Green, Gavin Koh, Cindy S. Chu, François Nosten, Ric N. Price, Nicholas Day, Sir Nicholas White
Podjanee Jittamala, Sasithon Pukrittayakamee, Elizabeth A. Ashley, François Nosten, Borimas Hanboonkunupakarn, Sue J. Lee, Praiya Thana, Kalayanee Chairat, Daniel Blessborn, Salwaluk Panapipat, Sir Nicholas White, Nicholas Day, Joel Tärning
Discussion(0)
No comments yet. Be the first to comment.